3 “Huh?” Moments in EDM Last Week

Sound Remedy is going back on tour

Credit: Turk Photos

Several months after announcing his last public performance would be at Resolution 2017 on New Year’s Eve in Seattle, Sound Remedy is going back on tour in 2018. Huh?

As we mentioned last week with LCD Soundsystem, situations like this aren’t exactly rare in music. Retirements often become breaks, and believing an artist or group is ever performing their final show is foolish. Breaks can be good, as the grind that artists face would wear most people down. Taking a year off from touring makes sense, and we’re happy Sound Remedy will be back relatively soon.

He initially announced the return on August 3rd, with a lengthy explanation via his Facebook page.

A few weeks later, he announced his return to public performing, with a tour in 2018 in the works. In his time away from the stage, Sound Remedy seemingly kept busy, releasing plenty of original music while connecting with fans on a regular basis on social media. His playlist entitled 2017 on Soundcloud, features 47 new tracks, and that doesn’t even include his latest album Point Five, which was released in late-June.

The return of Sound Remedy is more than welcome, and artists could probably use a break from touring more often than they take them. Even though that’s the case, why retire at all? It’s not the worst thing ever, and we’d prefer artists performing rather than not. But, let’s just start using ‘hiatus’ and ‘break’ from now on, if anything needs to be said at all.

FDA grants therapy designation for MDMA-assisted psychotherapy for PTSD

Sufferers from posttraumatic stress disorder (PTSD) may soon be able to legally use MDMA therapeutically. Huh?

The Multidisciplinary Association for Psychedelic Studies (MAPS) announced that they and the FDA have reached an agreement for the design of new trials of MDMA-assisted psychotherapy for patients with severe PTSD. According to the press release, this is the first time ever psychedelic-assisted psychotherapy will be evaluated in Phase 3 trials for possible prescription use, and there’s plenty of reason to be hopeful.

“In MAPS’ completed Phase 2 trials with 107 participants, 61% no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. All Phase 2 participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.” – via MAPS

We couldn’t be happier about this development, and will continue to advocate for the work that organizations like MAPS does. According to the release, donations are necessary to complete the research, with no funding currently available from the usual resources. MAPS still needs $12.5 million, so if you’d like to donate, you can visit maps.org/donate.